$20.84
+0.25 (+1.21%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CGEM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 1 with posted results
Held by 10 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, +5 more) · FINRA short interest 19.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHANCT07738822Safety and TolerabilityNon-randomized · Open-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: Velinotamig specified dose on specified days. | Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | 72 | Jan 2029 | ≤ 896 d | 2026-07-31 |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's DiseaseNCT07041099Safety and TolerabilityNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CLN-978 | Sjögren, Sjogren Disease, Sjogren's Syndrome | 36 | 2028-03-15 | in 574 d | 2026-08-11 |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid ArthritisNCT06994143Incidence and severity of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CLN-978 | Rheumatoid Arthritis (RA | 37 | 2027-12-30 | in 498 d | 2026-05-15 |
| A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML PatientsNCT07722767Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclaxNon-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: CLN-049, Azacitidine, Venetoclax | AML (Acute Myeloid Leukemia) | 90 | 2027-09-30 | in 407 d | 2026-07-23 |
| CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)NCT05143996Number of treatment emergent events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CLN-049 | Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | 60 | Jan 2027 | ≤ 165 d | 2026-01-16 |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusNCT06613360Safety and tolerabilityNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CLN-978 | SLE, SLE (Systemic Lupus) | 24 | Dec 2026 | ≤ 134 d | 2026-06-05 |
| A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)NCT05879744Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: CLN-978 | NHL, NHL, Relapsed, Adult | 90 | Nov 2026 | ≤ 103 d | 2024-05-02 |
| A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple MyelomaNCT06381141Proportion of participants reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: CLN-619 | Multiple Myeloma | 30 | Sep 2026 | ≤ 42 d | 2025-09-18 |
| A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsNCT05117476Dose Escalation: TEAEsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: CLN-619, Pembrolizumab, Paclitaxel, Carboplatin AUC 6, pemetrexed, Datopotamab deruxtecan-dlnk (Dato-DXd) | Advanced Solid Tumor, NSCLC | 440 | Mar 2026 | — | 2025-11-24 |
| A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerNCT04036682All Cohorts: The rate and severity of treatment emergent AEs.Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: CLN-081 | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 284 | 2025-10-13actual | — | 2026-06-17 |
| CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid TumorsNCT06035744Dose EscalationNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Company decision | Drug: CLN-617, Pembrolizumab | Advanced Solid Tumor | 23 | 2026-06-16actual | — | 2026-06-18 |
| Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)NCT03682055results2023-08-15All Cohorts: The Frequency, Severity, and Duration of AEs and DLTs, AEs Leading to Discontinuation, and AEs Leading to Death.Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Lack of efficacy | Drug: VK-2019 | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | 14 | 2020-06-23actual | — | 2023-08-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19